Savara (SVRA) Revenue (2013 - 2020)

Name: Savara (SVRA) Revenue (2013 - 2020) | Business Quant
Creator: Business Quant

Savara (SVRA) reported Revenue of $1000.0 for Q4 2020, down 99.61% on a QoQ basis from $256000.0 in Q3 2020.

Savara (SVRA) has 5 years of Revenue data on file, last reported at $1000.0 in Q4 2020.

Quarterly Revenue changed N/A year-over-year to $1000.0 in Q4 2020, while the trailing twelve-month figure through Mar 2022 was $1000.0 (changed N/A YoY) and the FY2020 annual result came in at $257000.0, changed N/A from the prior year.
Revenue fell to $1000.0 in Q4 2020 per SVRA's latest filing, from $256000.0 in the prior quarter.
Across five years, Revenue topped out at $400000.0 in Q4 2016 and bottomed at -$94000.0 in Q2 2017.
The 3-year median for Revenue is $69500.0 (2016), against an average of $117000.0.
Peak annual rise in Revenue reached 640.74% in 2016, while the deepest fall reached 640.74% in 2016.
Tracing SVRA's Revenue over 3 years: stood at $400000.0 in 2016, then plunged by 123.5% to -$94000.0 in 2017, then surged by 101.06% to $1000.0 in 2020.
Per Business Quant, the three latest SVRA Revenue figures stand at $1000.0 (Q4 2020), $256000.0 (Q3 2020), and -$94000.0 (Q2 2017).

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	306.30 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	2.99 Bn
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	3.61 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	1.17 Bn
10	Savara	1.30 Bn	1.30 Bn	-	-

Download Data 🔒